Skip to main content
Clinical Trials/NL-OMON40709
NL-OMON40709
Recruiting
Phase 4

Comparison of Titanium-Nitride-Oxide coated Bio-Active-Stent (Optimax*) to the Drug (Everolimus) -Eluting Stent (Synergy*) in Acute Coronary Syndrome - TIDES-ACS

S0 sites500 target enrollmentTBD

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Not specified
Sponsor
S
Enrollment
500
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Sponsor
S

Eligibility Criteria

Inclusion Criteria

  • Patients presenting with non ST\-elevation or ST\-elevation acute coronary syndrome

Exclusion Criteria

  • \- Age \< 18 years
  • \- Expected survival \< 1 year
  • \- Allergy to aspirin, clopidogrel, prasugrel or ticagrelol
  • \- Allergy to heparins, glycoprotein IIb/IIIa inhibitors or bivalirudin
  • \- Allergy to everolimus
  • \- Active bleeding or significant increased risk of bleeding
  • \- Stent length longer than 28 mm needed
  • \- Stent diameter \> 4\.0 mm needed
  • \- Previous coronary artery bypass surgery (CABG)
  • \- Aorto\-ostial lesion

Outcomes

Primary Outcomes

Not specified

Similar Trials